OASIS Wins Grand Prize at IDea Incubator Competition Held in Collaboration with Johnson & Johnson Innovation – JLABS
Four Finalists Present ID Innovations at First Fully Virtual IDWeek
Arlington, VA – Oct. 20, 2020 – The Infectious Diseases Society of America’s (IDSA) Foundation is thrilled to announce the winners of the IDea Incubator, a pitch-style competition held this year in collaboration with Johnson & Johnson Innovation – JLABS at the first IDWeek conference held virtually.
OASIS (Outpatient Automated Stewardship Information System) took top prize at the third annual IDea Incubator, a competition showcasing inventions, products and devices to improve patient care for infectious diseases. Four finalists were chosen from a competitive pool of applicants to present their solutions addressing challenging problems, including the need for more effective PPE during this current pandemic.
Awarded the grand prize of $10,000 for generating and distributing antibiotic stewardship audits and feedback reports in outpatient settings were Holly Frost, M.D., assistant professor at Denver Health, and Sonal Munsiff, M.D., assistant professor at University of Rochester Medical Center.
The winning innovation is OASIS (Outpatient Automated Stewardship Information System). OASIS uses a statistical software program to abstract data from major electronic health record data warehouses, generate easy to read graphs and reports and email individualized reports to providers at pre-defined intervals. The program can be easily customized for nearly any antibiotic stewardship intervention or target. OASIS will help health care systems implement the CDC Core Elements of Outpatient Antibiotic Stewardship in a cost-effective manner that requires substantially less time than traditional methods.
“Through our unique public-private collaboration with BARDA, BLUE KNIGHT™, we set out to help unlock the collective strength of the global innovation community with the aim to tackle some of the world’s most pressing challenges—both known and unknown global health threats, including pandemic influenza and emerging infectious diseases,” said Rachel Rath, M.B.A, M.P.H, director of the BARDA Alliance for Johnson & Johnson Innovation – JLABS. “The IDea Incubator focuses on original ideas, technologies, science and potential solutions that align around our shared focus on combating infectious diseases.”
The other finalists:
Taylor Freeman, founder of Axon Park, and Farrukh Jafri, M.D., of White Plains Hospital were awarded first runner-up for their PPE VR Training Simulator, a cost-effective asynchronous virtual reality simulator teaching a structured, efficient, and safe method for donning and doffing PPE based on guidelines from the CDC and WHO. They were awarded $5,000.
Vidya Atluri, M.D., Ph.D., of University of Washington, Paul Pottinger, M.D., DTMH, FACP, FIDSA, of University of Washington Medical Center, and Lahari Rampur, M.D., of Kaiser Permanente Washington were awarded second runner-up for their customizable mobile app PAl-ergy. This mobile app assists providers in handling beta-lactam allergies according to their institutional guidelines. They were awarded $2,500.
Steve Kalish, M.D., of North Shore University Hospital System & Swedish Hospital received an honorary mention for his Single-Handed Donning of Hygienic Gloves: Apparatus and Method innovation, which is a convenient method for rapidly, aseptically, and inexpensively donning hygienic FDA-approved gloves with a single hand. He did not receive a cash prize, but was honored due to the high quality of his innovation.
“Receiving feedback from the judges who are experts in their field and presenting in front of an audience of infectious diseases professionals provides you the opportunity to network and increase awareness of your innovation,” said Sai Dodda, PharmD, one of the winners of the 2019 IDea Incubator for his outpatient parenteral antimicrobial therapy (OPAT) monitoring device.
This year applications for the IDea Incubator were reviewed and scored by members of the IDSA Telehealth and Technology Workgroup, in addition to a group of experts in technology and innovation, to determine the finalists for the live competition. Finalists then presented their innovations to a panel of judges, including Jonathan Burkland, managing director of River Corporate Advisors, LLC; Erik Douglas, Ph.D., director, Digital Device Innovation with J&J Consumer Products U.S.; Audrey Odom John, M.D., Ph.D., chief of the Division of Pediatric Infectious Diseases at the Children’s Hospital of Philadelphia and 2018 IDea Incubator Grand Prize winner; and Richard Page, managing director of Ladenburg Thalmann. We were also proud to have the creator and host of the competition, Javeed Siddiqui, M.D., MPH, co-founder and chief medical officer of TeleMed2U.
Launched at IDWeek 2018, the IDea Incubator was the brainchild of Javeed Siddiqui, M.D., MPH, head of the IDSA Telehealth and Emerging Technologies Workgroup. He moderated the 2020 IDea Incubator competition and, as in previous years, was essential in planning the event.
For more information regarding the IDea Incubator and the finalists, please visit https://www.idsafoundation.org/ideaincubator/.
About IDWeek
IDWeek 2020TM was the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2020 took place Oct. 20-25 globally, online. For more information, visit www.idweek.org.
About IDSA Foundation
The IDSA Foundation is the nation’s leading non-profit organization committed to reducing the burdens of infectious diseases. Founded in 2001, the IDSA Foundation is the Infectious Diseases Society of America’s charitable arm, committed to providing career development opportunities, supporting education and funding research. The Foundation aims to empower the next generation of ID leaders, to support innovative research and to advocate for advancements in patient care.
About Johnson & Johnson Innovation – JLABS
Johnson & Johnson Innovation – JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.
Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services with the goal of stimulating innovation and incubation of science and technologies that aim to improve health security and response through companies with science and technologies focused on public health threats and emerging infectious diseases with the goal of improving health security and response. Visit jlabs.jnjinnovation.com for more information about JLABS and BLUE KNIGHT™, including how to apply.